Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares OutstandingShares Outstanding
Ratios

Tandem Diabetes Care (TNDM) Shares Outstanding (2016 - 2026)

Tandem Diabetes Care filings provide 13 years of Shares Outstanding readings, the most recent being $68.3 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 3.06% to $68.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $68.3 million, a 3.06% increase, with the full-year FY2025 number at $68.3 million, up 3.06% from a year prior.
  • Shares Outstanding hit $68.3 million in Q4 2025 for Tandem Diabetes Care, up from $67.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $68.3 million in Q4 2025 to a low of $62.6 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $64.8 million (2023), compared with a mean of $65.1 million.
  • Biggest five-year swings in Shares Outstanding: rose 4.16% in 2021 and later fell 0.07% in 2024.
  • Tandem Diabetes Care's Shares Outstanding stood at $63.8 million in 2021, then grew by 1.07% to $64.5 million in 2022, then rose by 1.61% to $65.6 million in 2023, then grew by 1.09% to $66.3 million in 2024, then rose by 3.06% to $68.3 million in 2025.
  • The last three reported values for Shares Outstanding were $68.3 million (Q4 2025), $67.8 million (Q3 2025), and $67.5 million (Q2 2025) per Business Quant data.